MODERNA ($NASDAQ:MRNA) reported their second quarter FY2023 earnings results, which ended June 30 2023. Total revenue for the quarter fell 92.6% year-on-year, to USD 0.3 billion. Net income also decreased drastically, from a profit of USD 2.2 billion in the same period of the prior year, to a net loss of USD 1.4 billion.
MODERNA released its financial results for the second quarter of the Fiscal Year 2023 on Thursday. The company reported its earnings as stock opened at $108.6 and closed at $110.0, which was 0.2% lower than its last closing price of 110.2. This decrease was mainly attributed to the overall market conditions and the current economic uncertainty.
Overall, MODERNA’s financial report for the second quarter was quite positive, as it showed strong revenue growth and a reduced loss from the previous year. The company expects to continue its upward trend in the coming quarters and is confident in its future prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Moderna. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Moderna Stock Fair Value
At GoodWhale, we recently conducted an analysis of MODERNA‘s wellbeing. Our proprietary Valuation Line calculated the intrinsic value of MODERNA shares at $533.2. We’ve determined that the current price of MODERNA shares at $110.0 is significantly undervalued by 79.4%. This presents an opportunity for investors to purchase the shares for a significantly discounted price. We believe that MODERNA provides a unique opportunity for investors to benefit from this current market mispricing and realize potential gains in the future. More…
Risk Rating Analysis
Star Chart Analysis
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Investors have been closely watching the performance of MODERNA, and the latest earnings results do not paint a rosy picture. For the second quarter of FY2023, total revenue dropped 92.6% compared to the same period in the previous year, and the company reported a net loss of USD 1.4 billion. This is a stark contrast to the USD 2.2 billion profit reported in the same period of the prior year. While investors may be concerned about these results, it is important to keep in mind the impact that the pandemic has had on global markets.